Uncategorized

Novartis CEO ‘continuing to evaluate’ in vivo CAR-Ts, but no deals in the works

Novartis is “continuing to evaluate” the in vivo CAR-T space, although the pharma’s CEO has told Fierce Biotech that no deals are currently in the works.​Read More

Published

1 week ago

on

Novartis is “continuing to evaluate” the in vivo CAR-T space, although the pharma’s CEO has told Fierce Biotech that no deals are currently in the works.​Read More

Related Topics:

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version